Table 1.

Demographic and baseline characteristics by presence of CNS metastases, n (%)

All patients (n = 1,012)No CNS metastases (n = 635)Any CNS metastases (n = 377)CNS metastases at MBC diagnosis (n = 75)CNS metastases after MBC diagnosis (n = 302)
Age, ya
 <50394 (38.9)232 (36.5)162 (43.0)33 (44.0)129 (42.7)
 50–64406 (40.1)249 (39.2)157 (41.6)33 (44.0)124 (41.1)
 65+212 (20.9)154 (24.3)58 (15.4)9 (12.0)49 (16.2)
Race
 White799 (79.0)496 (78.1)303 (80.4)60 (80.0)243 (80.5)
 Nonwhite213 (21.0)139 (21.9)74 (19.6)15 (20.0)59 (19.5)
Hormone receptor statusa,b
 Positive535 (52.9)368 (57.9)167 (44.3)24 (32.0)143 (47.4)
 Negative439 (43.4)248 (39.1)191 (50.7)48 (64.0)143 (47.4)
 Unknown38 (3.8)19 (3.0)19 (5.0)3 (4.0)16 (5.3)
Number of metastatic sitesa
 1467 (46.1)324 (51.0)143 (37.9)25 (33.3)118 (39.1)
 2+545 (53.9)311 (49.0)234 (62.1)50 (66.7)184 (60.9)
ECOG PS at MBC diagnosisb
 0–1457 (45.2)300 (47.2)157 (41.6)20 (26.7)137 (45.4)
 2+64 (6.3)38 (6.0)26 (6.9)6 (8.0)20 (6.7)
 Unknown/missing491 (48.5)297 (46.8)194 (51.5)49 (65.3)145 (48.0)
Stage at initial diagnosis
 Stage IV277 (27.4)181 (28.5)96 (25.5)17 (22.7)79 (26.2)
 Stage I–III with early relapse (≤12 mo)137 (13.5)88 (13.9)49 (13.0)11 (14.7)38 (12.6)
 Stage I–III with late relapse (>12 mo)598 (59.1)366 (57.6)232 (61.5)47 (62.7)185 (61.3)
Prior therapy (stage I–III only)b,c
 Trastuzumab-based therapy without hormones46 (4.5)24 (3.8)22 (5.8)10 (13.3)12 (4.0)
 Trastuzumab-based therapy with hormones10 (1.0)7 (1.1)3 (0.8)03 (1.0)
 Hormones only58 (5.7)40 (6.3)18 (4.8)4 (5.3)14 (4.7)
 Hormones and chemotherapy164 (16.2)106 (16.7)58 (15.4)10 (13.3)48 (15.9)
 Chemotherapy only320 (31.6)192 (30.2)128 (33.9)28 (37.3)100 (33.1)
 Other therapy5 (0.5)5 (0.8)000
 No prior therapy132 (13.0)80 (12.6)52 (13.8)6 (8.0)46 (15.2)
  • aCNS metastases versus no CNS metastases (P < 0.05).

  • bCNS metastases at MBC diagnosis versus CNS metastases developed after MBC diagnosis (P < 0.05).

  • cPatients with stage IV MBC did not receive any adjuvant/neoadjuvant therapy. Percentages calculated from the total number of patients in the column. Herceptin was approved for use in the adjuvant setting in November 2006, which was after completion of enrollment into registHER (February 2006).